TrialDiabetes care2022

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

Ofri Mosenzon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.